Delivering Type I Interferon to Dendritic Cells Empowers Tumor Eradication and Immune Combination Treatments
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
An ideal generic cancer immunotherapy should mobilize the immune system to destroy tumor cells without harming healthy cells and remain active in case of recurrence. Furthermore, it should preferably not rely on tumor-specific surface markers, as these are only available in a limited set of malignancies. Despite approval for treatment of various cancers, clinical application of cytokines is still impeded by their multiple toxic side effects. Type I IFN has a long history in the treatment of cancer, but its multifaceted activity pattern and complex side effects prevent its clinical use. Here we develop AcTakines (Activity-on-Target cytokines), optimized (mutated) immunocytokines that are up to 1,000-fold more potent on target cells, allowing specific signaling in selected cell types only. Type I IFN-derived AcTaferon (AFN)-targeting Clec9A+ dendritic cells (DC) displayed strong antitumor activity in murine melanoma, breast carcinoma, and lymphoma models and against human lymphoma in humanized mice without any detectable toxic side effects. Combined with immune checkpoint blockade, chemotherapy, or low-dose TNF, complete tumor regression and long-lasting tumor immunity were observed, still without adverse effects. Our findings indicate that DC-targeted AFNs provide a novel class of highly efficient, safe, and broad-spectrum off-the-shelf cancer immunotherapeutics with no need for a tumor marker. Significance: Targeted type I interferon elicits powerful antitumor efficacy, similar to wild-type IFN, but without any toxic side effects. Cancer Res; 78(2); 463–74. ©2017 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929 · cited 4×
“The cancer-immunity cycle indicates the sequential involvement of several steps for complete tumor eradication (21).”
BackgroundInfluentialChimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413 · cited 1×
“treating hematological malignancies (48), the potential of CARs in solid tumors is greatly hampered by the lack of unique tumor-associated antigens, inefficient homing to tumor sites and the immunosuppressive microenvironment of solid tumors (49).”
BackgroundCalreticulin exposure dictates the immunogenicity of cancer cell death
Obeid, M., Tesniere, A., Ghiringhelli, F., Fimia, G. M., Apetoh, L., Perfettini, J.-L., Castedo, M., Mignot, G., Panaretakis, T., Casares, N., et al. (2007) · Nature Medicine · doi:10.1038/nm1523 · Cited by 3,216 · cited 1×
“These include the induction of immunogenic cancer cell death necessary for the release of tumor antigens (which doxorubicine is known to promote (43)), the increased antigen presentation capacities of DC (shaped by both type I IFN and TNF), improved priming and activation of T lymphocytes (positively influenced by imm…”
BackgroundRadiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
Twyman-Saint Victor, C., Rech, A. J., Maity, A., Rengan, R., Pauken, K. E., Stelekati, E., Benci, J. L., Xu, B., Dada, H., Odorizzi, P. M., et al. (2015) · Nature · doi:10.1038/nature14292 · Cited by 2,434 · cited 1×
“To escape CTLkilling during anti-PDL1 treatment, tumor-infiltrating or –resident lymphocytes upregulate CTLA4 expression, and vice versa (39,40).”
BackgroundDeng, L., Liang, H., Xu, M., Yang, X., Burnette, B., Arina, A., Li, X.-D., Mauceri, H., Beckett, M., Darga, T., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.10.019 · Cited by 2,182 · cited 1×
“Furthermore, endogenous IFN is essential for cancer immunosurveillance (6,7), and for anti-cancer therapies including chemotherapy, radiotherapy, immunotherapies and checkpoint inhibition (5,8-13).”
BackgroundBatf3 Deficiency Reveals a Critical Role for CD8α + Dendritic Cells in Cytotoxic T Cell Immunity
Hildner, K., Edelson, B. T., Purtha, W. E., Diamond, M., Matsushita, H., Kohyama, M., Calderon, B., Schraml, B. U., Unanue, E. R., Diamond, M. S., et al. (2008) · Science · doi:10.1126/science.1164206 · Cited by 2,081
STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors
Woo, S.-R., Fuertes, M. B., Corrales, L., Spranger, S., Furdyna, M. J., Leung, M. Y. K., Duggan, R., Wang, Y., Barber, G. N., Fitzgerald, K. A., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.10.017 · Cited by 1,917
Koyama, S., Akbay, E. A., Li, Y. Y., Herter-Sprie, G. S., Buczkowski, K. A., Richards, W. G., Gandhi, L., Redig, A. J., Rodig, S. J., Asahina, H., et al. (2016) · Nature Communications · doi:10.1038/ncomms10501 · Cited by 1,580
Spranger, S., Dai, D., Horton, B., & Gajewski, T. F. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.04.003 · Cited by 1,441
Type I interferons in anticancer immunity
Zitvogel, L., Galluzzi, L., Kepp, O., Smyth, M. J., & Kroemer, G. (2015) · Nature Reviews Immunology · doi:10.1038/nri3845 · Cited by 1,305
Cited by
Dendritic cells in cancer immunology and immunotherapy
Wculek, S. K., Cueto, F. J., Mujal, A. M., Melero, I., Krummel, M. F., & Sancho, D. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0210-z · Cited by 2,574
Cytokines in clinical cancer immunotherapy
Berraondo, P., Sanmamed, M. F., Ochoa, M. C., Etxeberria, I., Aznar, M. A., Pérez-Gracia, J. L., Rodríguez-Ruiz, M. E., Ponz-Sarvise, M., Castañón, E., & Melero, I. (2019) · British Journal of Cancer · doi:10.1038/s41416-018-0328-y · Cited by 1,205
Harnessing innate immunity in cancer therapy
Demaria, O., Cornen, S., Daëron, M., Morel, Y., Medzhitov, R., & Vivier, E. (2019) · Nature · doi:10.1038/s41586-019-1593-5 · Cited by 957
Dendritic Cells and Their Role in Immunotherapy
Gardner, A., de Mingo Pulido, Á., & Ruffell, B. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00924 · Cited by 485
Dendritic cells as orchestrators of anticancer immunity and immunotherapy
Heras-Murillo, I., Adán-Barrientos, I., Galán, M., Wculek, S. K., & Sancho, D. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00859-1 · Cited by 383
Metadata
- Authors
- Cauwels, A., Van Lint, S., Paul, F., Garcin, G., De Koker, S., Van Parys, A., Wueest, T., Gerlo, S., Van der Heyden, J., Bordat, Y., Catteeuw, D., Rogge, E., Verhee, A., Vandekerckhove, B., Kley, N., Uzé, G., & Tavernier, J.
- Venue
- Cancer Research
- Published
- 2018-01-15
- Volume
- 78
- Issue
- 2
- Pages
- 463-474
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2770901637
- Cited by
- 97
- References
- 14
- FWCI
- 3.35
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Delivering Type I Interferon to Dendritic Cells Empowers Tumor Eradication and Immune Combination Treatments. https://app.cochat.ai/papers/10.1158/0008-5472.can-17-1980
- The paper
- Cauwels, A., Van Lint, S., Paul, F., Garcin, G., De Koker, S., Van Parys, A., Wueest, T., Gerlo, S., Van der Heyden, J., Bordat, Y., Catteeuw, D., Rogge, E., Verhee, A., Vandekerckhove, B., Kley, N., Uzé, G., & Tavernier, J. (2018). Delivering Type I Interferon to Dendritic Cells Empowers Tumor Eradication and Immune Combination Treatments. Cancer Research. https://doi.org/10.1158/0008-5472.can-17-1980
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.